These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 29781878)

  • 1. HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.
    Andreatta K; Chang S; Martin R; Acosta R; Daeumer M; Thielen A; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2018 Sep; 79(1):e45-e51. PubMed ID: 29781878
    [No Abstract]   [Full Text] [Related]  

  • 2. Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Adams JL; Byrne D; Pepe R; Gray A; Baxter JD
    Antivir Ther; 2016; 21(2):175-80. PubMed ID: 26308882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
    Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
    HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-tablet antiretroviral treatment (once daily).
    Andany N; Gold WL
    CMAJ; 2016 Sep; 188(13):971. PubMed ID: 27221274
    [No Abstract]   [Full Text] [Related]  

  • 9. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
    Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
    BMC Infect Dis; 2016 Nov; 16(1):718. PubMed ID: 27894270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
    Ba S; Raugi DN; Smith RA; Sall F; Faye K; Hawes SE; Sow PS; Seydi M; Gottlieb GS;
    Clin Infect Dis; 2018 Oct; 67(10):1588-1594. PubMed ID: 29672676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
    Nozza S; Poli A; Ripa M; Galli L; Chiappetta S; Spagnuolo V; Rovelli C; Lazzarin A; Castagna A; Tambussi G
    J Antimicrob Chemother; 2017 Feb; 72(2):632-633. PubMed ID: 27798217
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review.
    Naccarato MJ; Yoong DM; Fong IW; Gough KA; Ostrowski MA; Tan DHS
    J Int Assoc Provid AIDS Care; 2018; 17():2325957417752260. PubMed ID: 29385867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
    Lambert-Niclot S; Allavena C; Grude M; Flandre P; Sayon S; Andre E; Wirden M; Rodallec A; Jovelin T; Katlama C; Calvez V; Raffi F; Marcelin AG
    J Antimicrob Chemother; 2016 Aug; 71(8):2248-51. PubMed ID: 27231280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate: Erratum.
    J Acquir Immune Defic Syndr; 2018 Dec; 79(4):e111. PubMed ID: 30365453
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
    Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
    HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide.
    Dickson S; Gabriel N; Hernandez I
    AIDS; 2022 Dec; 36(15):2225-2227. PubMed ID: 36205353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.
    Ngo Bell EC; Vandenhende MA; Caldato S; Saunier A; Bellecave P; Tumiotto C; Avettand-Fenoel V; Hessamfar M; Morlat P; Bonnet F
    J Antimicrob Chemother; 2017 Sep; 72(9):2681-2683. PubMed ID: 28582509
    [No Abstract]   [Full Text] [Related]  

  • 20. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
    Post FA; Tebas P; Clarke A; Cotte L; Short WR; Abram ME; Jiang S; Cheng A; Das M; Fordyce MW
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):180-184. PubMed ID: 27673443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.